Introduction {#s1}
============

Gout is mainly caused by elevated serum uric acid (UA) levels [@pone.0007729-Campion1]. Several studies showed significant association between single nucleotide polymorphism (SNP) markers in *SLC2A9* gene (solute carrier family 2, member 9, also known as *GLUT9* gene) and serum UA levels as well as susceptibility to gout [@pone.0007729-Li1]--[@pone.0007729-Dehghan1]. Additionally, Dehghgan et al. reported association between markers in genes *ABCG2* and *SLC17A3* with both, serum UA levels and gout in a large cohort [@pone.0007729-Dehghan1]. Very recently, Kolz et al. conducted a meta-analysis of 14 genome-wide association (GWA) studies on serum UA levels including a total of 28,141 participants [@pone.0007729-Kolz1]. Nine loci with significant associations to serum UA levels were found, namely the genes *PDZK1*, *GCKR*, *LRRC16A*, *SLC16A9* and *SLC22A11* together with the previously reported findings in *ABCG2, SLC2A9* and *SLC17A1*-*SLC17A3*, as well as the intensively studied *SLC22A12* gene encoding for URAT1. Therefore, five novel loci associated with serum UA levels emerged from this meta-analysis [@pone.0007729-Kolz1]. The advantage of this GWA-based meta-analysis is its power to detect novel common variants with relatively small phenotypic effects on serum UA due to the large sample size.

We analyzed these new and known loci for their association with the clinical phenotype gout in a case control study.

Elevated serum UA levels are potentially increasing the risk for coronary artery disease (CAD) and myocardial infarction (MI) [@pone.0007729-Culleton1]--[@pone.0007729-Niskanen1]. We therefore tested additionally for the influence of these SNP markers on the susceptibility to CAD in our German MI Family Study.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

The Ethics committee of the University of Regensburg approved the study protocol and all participants gave their written informed consent at the time of inclusion and again at the time of follow-up investigations. The study was in accordance with the principles of the current version of the Declaration of Helsinki.

Case-Control Samples and Phenotyping {#s2b}
------------------------------------

All individuals of this study participated in the German MI Family Study (total *n* = 7,575). Recruitment process, selection criteria and study details have been reported previously [@pone.0007729-Stark1]. A total of *n* = 683 unrelated individuals (*n* = 480 males, *n* = 203 females) with the diagnosis of gout were selected from the German MI Family Study. Phenotyping was carried out as reported previously [@pone.0007729-Stark1]. In brief, the phenotype gout was established using medical history readings and self-reported history of gout.

Controls (*n* = 1,563) were unrelated individuals from our German MI Family Study who neither had any indication of gout nor were they medicated with uricostatic or uricosuric agents at any time during follow-up (*n* = 871 males, *n* = 692 females). Phenotypic details are shown in [Table 1](#pone-0007729-t001){ref-type="table"}.

10.1371/journal.pone.0007729.t001

###### Characteristics of gout case and control study sample.
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  Variable                                                          Gout cases (*n* = 683)   Gout-free controls (*n* = 1,563)   *p*-value
  ---------------------------------------------------------------- ------------------------ ---------------------------------- -----------
  Gender, % male (*n*)                                                    70.3 (480)                    55.7 (871)              \<0.0001
  Age, years (range) [a](#nt102){ref-type="table-fn"}                 58.3±9.5 (23--84)             58.5±8.6 (28--87)            n\. s.
  Medication with diuretics, % (*n*)                                      36.1 (221)                    22.0 (341)              \<0.0001
  MI or severe CAD, % (*n*)                                               61.1 (417)                    58.2 (909)               n\. s.
  Hypercholesterolemia [b](#nt103){ref-type="table-fn"}, % (*n*)          70.5 (481)                   66.9 (1,046)              n\. s.
  Lipid lowering medication, % (*n*)                                      50.1 (307)                    44.9 (701)                0.03
  LDL-C, mg/dl                                                            150.9±41.0                    147.8±38.7               n\. s.
  HDL-C, mg/dl                                                            50.7±14.2                     55.3±15.7               \<0.0001
  Hypertension [c](#nt104){ref-type="table-fn"}, % (*n*)                  86.6 (580)                   83.7 (1,269)               0.05
  Antihypertensive therapy, % (*n*)                                       83.5 (512)                   72.6 (1,134)             \<0.0001
  Systolic blood pressure, mmHg                                           139.0±19.1                    135.8±18.5               0.0003
  Diastolic blood pressure, mmHg                                          84.0±10.3                      82.0±9.8               \<0.0001
  Type 2 diabetes [d](#nt105){ref-type="table-fn"}, % (*n*)               16.3 (111)                    10.6 (165)               0.0002
  Smoking [e](#nt106){ref-type="table-fn"}, % (*n*)                       66.1 (451)                    60.4 (942)                0.009
  BMI, kg/m^2^                                                             28.1±3.9                      26.8±3.7               \<0.0001

Values denote means±standard deviations unless indicated otherwise. n. s., not significant; CAD, coronary artery disease; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index.

At inclusion to study.

Defined as LDL-C ≥160 mg/dL or intake of lipid lowering medication.

Defined as blood pressure ≥140/90 mmHg or ongoing antihypertensive therapy.

Defined as history of diabetes mellitus or intake of antidiabetic medication.

Former or current smoking habit.

Furthermore, a large case-control sample was established from the German MI Family Study including *n* = 1,473 CAD/MI unrelated cases (*n* = 856 males, *n* = 617 females) and *n* = 1,241 unrelated CAD/MI-free control individuals (*n* = 336 males, *n* = 905 females). MI was diagnosed according to MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) diagnostic criteria (<http://www.ktl.fi/publications/monica/manual/index.htm>). Severe CAD was defined as prior MI, treatment with percutaneous coronary intervention or coronary artery bypass graft. Cardiovascular risk factors and phenotypic details are summarized in [Table 2](#pone-0007729-t002){ref-type="table"}.

10.1371/journal.pone.0007729.t002

###### Characteristics of CAD case and control study sample.
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  Variable                                                          CAD cases (*n* = 1,473)   CAD-free controls (*n* = 1,241)   *p*-value
  ---------------------------------------------------------------- ------------------------- --------------------------------- -----------
  Gender, % male (*n*)                                                    58.1 (856)                    27.1 (336)              \<0.0001
  Age at inclusion, years (range)                                      60.2±8.5 (32--90)             56.4±9.9 (29--84)          \<0.0001
  Age at first CAD event, years (range)                                54.5±9.1 (24--89)                    \-                     \-
  MI, % (*n*)                                                            75.6 (1,114)                       \-                     \-
  Gout, % (*n*)                                                           15.5 (228)                     8.8 (109)              \<0.0001
  Hypercholesterolemia [a](#nt108){ref-type="table-fn"}, % (*n*)         83.4 (1,228)                   29.3 (363)              \<0.0001
  Lipid lowering medication, % (*n*)                                      66.7 (982)                    38.2 (474)              \<0.0001
  LDL-C, mg/dl                                                            149.4±42.6                    146.1±34.9               0.0313
  HDL-C, mg/dl                                                             51.4±13.8                     61.6±15.3              \<0.0001
  Hypertension [b](#nt109){ref-type="table-fn"}, % (*n*)                 94.4 (1,390)                   53.9 (669)              \<0.0001
  Antihypertensive therapy, % (*n*)                                      89.3 (1,316)                   35.0 (434)              \<0.0001
  Systolic blood pressure, mmHg                                           140.0±20.4                    132.6±18.2              \<0.0001
  Diastolic blood pressure, mmHg                                           82.6±10.4                     81.4±9.8                0.0054
  Type 2 diabetes [c](#nt110){ref-type="table-fn"}, % (*n*)               11.6 (171)                     4.2 (52)               \<0.0001
  Smoking [d](#nt111){ref-type="table-fn"}, % (*n*)                       62.7 (924)                    48.1 (597)              \<0.0001
  BMI, kg/m^2^                                                             27.3±3.6                      26.5±4.2               \<0.0001

Values denote means±standard deviations unless indicated otherwise. CAD, coronary artery disease; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index.

Defined as LDL-C ≥160 mg/dL or intake of lipid lowering medication.

Defined as blood pressure ≥140/90 mmHg or ongoing antihypertensive therapy.

Defined as history of diabetes mellitus or intake of antidiabetic medication.

Former or current smoking habit.

Recent GWA analyses [@pone.0007729-Erdmann1], [@pone.0007729-Samani1] using a part of the current study sample (*n* = 1,021) revealed no population stratification effects within unrelated individuals form the German MI Family Study using the genomic control method [@pone.0007729-Devlin1]. Therefore, no correction for population stratification was carried out.

SNP Selection and Genetic Analyses {#s2c}
----------------------------------

Genomic DNA isolation using the PureGene DNA Blood Kit (Qiagen, Hilden, Germany) and genotyping with 5′ exonuclease TaqMan® technology (Applied Biosystems, Foster City, CA, USA) was carried out as previously described [@pone.0007729-Stark1]. SNPs were selected from a recently published meta-analysis on serum UA levels [@pone.0007729-Kolz1] and our previous study [@pone.0007729-Stark1].

Statistical Analyses {#s2d}
--------------------

To determine whether the SNP genotypes of cases and controls deviated from Hardy-Weinberg equilibrium (HWE), actual and predicted genotype counts of both groups were compared by χ^2^-test. Differences in allele frequencies between dichotomous traits were calculated employing the same method. Prevalence odds ratios (OR) with their 95% confidence intervals (CI) were reported. Continuous parameters were compared by *t* test for normally distributed values or otherwise by non-parametric tests. Logistic regression was used to adjust for covariates differentially distributed in case-control cohorts. Full adjustment model for gout included gender, medication with diuretics, lipid lowering and antihypertensive therapy, high-density lipoprotein cholesterol (HDL-C), type 2 diabetes, smoking, and BMI. The corresponding model for CAD case-control sample included gender, age at inclusion, hypercholesterolemia, hypertension, type 2 diabetes, smoking, and BMI. Employing a model based on allele dosage, epistasis between SNPs was tested using a logistic regression analysis with the second SNP as a covariate. A two-sided *p*-value≤0.05 was considered statistically significant.

Statistical and association analyses were performed using JMP 7.0.2 (SAS Institute Inc, Cary, NC, USA) and PLINK v1.06 [@pone.0007729-Purcell1], respectively. Power analysis was carried out using G\*Power 3.0.10 employing a two-tailed exact test with minor allele frequencies (MAF) from controls [@pone.0007729-Faul1].

Results {#s3}
=======

Population Characteristics {#s3a}
--------------------------

In our first case-control cohort, gout cases (*n* = 683) were compared to control individuals (*n* = 1,563). Prevalence of cardiovascular risk factors and cardiovascular disease was high in both, gout cases and gout-free controls. However, we found no significant difference in number of reported MI or CAD events between gout cases (61.1% CAD/MI) and gout-free controls (58.2% CAD/MI). The proportion of women was lower in the gout group than in the control group. Gout cases were more often treated with diuretics as compared to controls. In addition and in concordance to the clinical manifestation of gout cases, the prevalence of type 2 diabetes and increased body mass index (BMI) was higher, and gout-free controls showed higher HDL-C levels, even after adjusting for gender (*p*\<0.001). The prevalence of hypercholesterolemia was equally distributed between the two groups, whereas hypertension and smoking were slightly more prevalent in gout cases ([Table 1](#pone-0007729-t001){ref-type="table"}).

In our second, large case-control sample for CAD/MI the incidence of established cardiovascular risk factors, such as male gender, type 2 diabetes, hypercholesterolemia, hypertension and smoking, as well as increased BMI, was higher in CAD/MI cases (*n* = 1,473) as compared to controls (*n* = 1,241) ([Table 2](#pone-0007729-t002){ref-type="table"}). We also found more individuals suffering from gout in our CAD/MI cases compared to CAD/MI-free controls ([Table 2](#pone-0007729-t002){ref-type="table"}).

Genetic Analyses {#s3b}
----------------

The cohorts were genotyped for markers listed in [Table 3](#pone-0007729-t003){ref-type="table"}. All SNPs fulfilled our criteria of at least 98% call rate in all sub-samples, except for rs734553 with a total call rate = 96.0%. Marker rs6855911 is in strong LD with rs734553 (*r^2^* = 0.94) and, therefore, can to some degree be used as a surrogate. Data for rs734553 were reported for completeness. Strong LD (*r^2^* = 0.967) exits between rs1183201 (*SLC17A1*) reported from Kolz et al. [@pone.0007729-Kolz1] and rs1165205 (*SLC17A3*) described by Dehghan et al. [@pone.0007729-Dehghan1]. Therefore, a distinction between these two genes on association level is not possible.

10.1371/journal.pone.0007729.t003

###### SNP marker used in analysis.
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  SNP           Position [a](#nt112){ref-type="table-fn"}   Major allele (1)   Minor allele (2)     Gene name(s)       Function      Call rate [b](#nt113){ref-type="table-fn"}
  ------------ ------------------------------------------- ------------------ ------------------ ------------------ --------------- --------------------------------------------
  rs12129861                Chr1: 144,437,046                      G                  A               *PDZK1*        5′ Intergenic                     98.4%
  rs780094                  Chr2: 27,594,741                       C                  T                *GCKR*          Intron 16                       99.2%
  rs734553                   Chr4: 9,532,102                       T                  G            *SLC2A9 GLUT9*      Intron 7                        96.0%
  rs6855911                  Chr4: 9,545,008                       A                  G            *SLC2A9 GLUT9*      Intron 7                        99.0%
  rs2231142                 Chr4: 89,271,347                       G                  T               *ABCG2*        Exon 5 Q141K                      99.2%
  rs742132                  Chr6: 25,715,550                       A                  G              *LRRC16A*         Intron 34                       99.4%
  rs1183201                 Chr6: 25,931,423                       T                  A              *SLC17A1*         Intron 3                        98.2%
  rs12356193                Chr10: 61,083,359                      A                  G              *SLC16A9*         Intron 5                        98.7%
  rs17300741                Chr11: 64,088,038                      G                  A              *SLC22A11*        Intron 4                        98.2%
  rs505802                  Chr11: 64,113,648                      T                  C           *SLC22A12 URAT1*   5′ Intergenic                     99.3%

on human genome build 18.

in total sample (*n* = 4,960).

### Association analysis of SNPs in the gout case-control sample {#s3b1}

Genotype distributions and allele frequencies in gout case-control cohort are shown in [Table 4](#pone-0007729-t004){ref-type="table"}. No deviation from HWE was observed for the ten genotyped markers in gout-free controls (*p*\>0.23). However, as previously reported [@pone.0007729-Stark1], rs6855911 in *SLC2A9* gene showed deviation from HWE in gout cases (*p* = 0.01). The proximate marker rs734553 also showed nominal deviation from HWE in gout cases (*p* = 0.05), whereas the other markers exhibited *p*-values\>0.18. Significant association with gout was found for rs734553 and rs6855911 located in intron 7 of *SLC2A9*, even after correction for multiple testing (ten SNPs) with *p~corr~* = 5.6\*10^−6^ and *p~corr~* = 1.1\*10^−6^, respectively. The *ABCG2* polymorphism rs2231142 remained significantly associated with gout after correction for multiple testing with *p~corr~* = 0.013. The power to detect nominal association with *p* = 0.05 and OR = 1.2 for the other SNPs ranged from 32.8% to 50.4% ([Table 4](#pone-0007729-t004){ref-type="table"}). Interaction between SNPs was analyzed using a model based on allele dosage. Nominal significance was observed between SNPs in *SLC2A9* (rs734553 and rs6855911) and rs742132 in *LRRC16A* with *p* = 0.038 and *p* = 0.024, respectively.

10.1371/journal.pone.0007729.t004

###### Association analysis results in gout case-control sample.
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                Gout case genotypes   Gout-free control genotypes   Allelic   Allelic OR   Adjusted [a](#nt115){ref-type="table-fn"}   Power [b](#nt116){ref-type="table-fn"}   Power [b](#nt116){ref-type="table-fn"}                                                                  
  ------------ --------------------- ----------------------------- --------- ------------ ------------------------------------------- ---------------------------------------- ---------------------------------------- ------- ------------- ------------------- ------------- ------- -------
  rs12129861            187                       334                 149       0.472                         394                                       752                                      394                     0.500      0.083      0.89 (0.78--1.02)      0.090      0.504   0.953
  rs780094              240                       325                 112       0.406                         558                                       747                                      247                     0.400      0.723      1.02 (0.90--1.17)      0.472      0.490   0.950
  rs734553              429                       211                 14        0.183                         846                                       553                                      103                     0.253   5.6\*10^−7^   0.66 (0.56--0.78)   3.7\*10^−6^   0.418   0.909
  rs6855911             429                       233                 15        0.194                         829                                       603                                      114                     0.269   1.1\*10^−7^   0.66 (0.56--0.77)   1.3\*10^−6^   0.430   0.918
  rs2231142             500                       168                  9        0.137                        1,241                                      299                                       12                     0.104   1.3\*10^−3^   1.37 (1.13--1.66)   2.2\*10^−3^   0.239   0.663
  rs742132              330                       276                 73        0.311                         764                                       644                                      145                     0.301      0.502      1.05 (0.91--1.20)      0.996      0.452   0.932
  rs1183201             187                       320                 161       0.481                         393                                       791                                      354                     0.487      0.679      0.97 (0.86--1.11)      0.691      0.504   0.953
  rs12356193            475                       182                 14        0.157                        1,069                                      436                                       40                     0.167      0.385      0.93 (0.78--1.10)      0.427      0.328   0.819
  rs17300741            176                       337                 158       0.487                         409                                       770                                      355                     0.482      0.798      1.02 (0.89--1.16)      0.981      0.504   0.953
  rs505802              317                       298                 64        0.314                         721                                       682                                      148                     0.315      0.917      0.99 (0.87--1.14)      0.783      0.459   0.936

Numbers of genotypes (11, 12, 22) according to alleles from [Table 3](#pone-0007729-t003){ref-type="table"}.

Model including gender, medication with diuretics, lipid lowering and antihypertensive therapy, HDL-C, type 2 diabetes, smoking, and BMI.

Power was calculated for the given OR using the respective MAF in controls and a two-tailed *p* = 0.05.

Furthermore, we had indication for gender interaction, as separate analyses in females and males revealed association with gout for both *SLC2A9* SNPs, whereas *ABCG2* SNP rs2231142 only showed significant association in males ([Table 5](#pone-0007729-t005){ref-type="table"}), but not in females ([Table 6](#pone-0007729-t006){ref-type="table"}). Full adjustment for gender, medication with diuretics, lipid lowering and antihypertensive therapy, HDL-C, type 2 diabetes, smoking, and BMI did not did not change the association results substantially ([Table 4](#pone-0007729-t004){ref-type="table"}). The same model without inclusion of gender was applied in males and females separately and did not lead to a significant change in *p*-values ([Table 5](#pone-0007729-t005){ref-type="table"} and [Table 6](#pone-0007729-t006){ref-type="table"}, respectively).

10.1371/journal.pone.0007729.t005

###### Association analysis results in male gout case-control sample.
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                Gout case genotypes   Gout-free control genotypes   Allelic   Allelic OR   Adjusted [a](#nt118){ref-type="table-fn"}                                                        
  ------------ --------------------- ----------------------------- --------- ------------ ------------------------------------------- ----- ----- ------- ------------- ------------------- -------------
  rs12129861            135                       232                 104       0.467                         218                      415   228   0.506      0.056      0.86 (0.73--1.00)      0.145
  rs780094              164                       225                 87        0.419                         315                      411   138   0.398      0.277      1.09 (0.93--1.28)      0.293
  rs734553              289                       159                 12        0.199                         453                      318   64    0.267   1.1\*10^−4^   0.68 (0.56--0.83)   6.0\*10^−4^
  rs6855911             291                       174                 12        0.208                         445                      349   69    0.282   2.2\*10^−5^   0.67 (0.55--0.80)   3.0\*10^−4^
  rs2231142             345                       124                  7        0.145                         686                      172    7    0.108   4.4\*10^−3^   1.41 (1.11--1.78)   3.3\*10^−3^
  rs742132              224                       203                 50        0.318                         438                      354   73    0.289      0.122      1.15 (0.96--1.36)      0.511
  rs1183201             126                       232                 109       0.482                         230                      440   188   0.476      0.757      1.03 (0.87--1.20)      0.991
  rs12356193            334                       127                  9        0.154                         586                      252   22    0.172      0.237      0.88 (0.71--1.09)      0.334
  rs17300741            116                       236                 120       0.504                         228                      426   199   0.483      0.295      1.09 (0.93--1.28)      0.421
  rs505802              215                       214                 48        0.325                         386                      384   92    0.330      0.812      0.98 (0.83--1.16)      0.781

Numbers of genotypes (11, 12, 22) according to alleles from [Table 3](#pone-0007729-t003){ref-type="table"}.

Model including medication with diuretics, lipid lowering and antihypertensive therapy, HDL-C, type 2 diabetes, smoking, and BMI.

10.1371/journal.pone.0007729.t006

###### Association analysis results in female gout case-control sample.
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                Gout case genotypes   Gout-free control genotypes   Allelic   Allelic OR   Adjusted [a](#nt120){ref-type="table-fn"}                                                        
  ------------ --------------------- ----------------------------- --------- ------------ ------------------------------------------- ----- ----- ------- ------------- ------------------- -------------
  rs12129861            52                        102                 45        0.482                         176                      337   166   0.493      0.720      0.96 (0.77--1.20)      0.315
  rs780094              76                        100                 25        0.373                         243                      336   109   0.403      0.288      0.88 (0.70--1.11)      0.734
  rs734553              140                       52                   2        0.144                         393                      235   39    0.235   1.4\*10^−4^   0.55 (0.40--0.75)   1.3\*10^−3^
  rs6855911             138                       59                   3        0.163                         384                      254   45    0.252   2.0\*10^−4^   0.58 (0.43--0.77)   9.7\*10^−4^
  rs2231142             155                       44                   2        0.119                         555                      127    5    0.100      0.256      1.22 (0.86--1.74)      0.265
  rs742132              106                       73                  23        0.295                         326                      290   72    0.315      0.426      0.91 (0.71--1.16)      0.391
  rs1183201             61                        88                  52        0.478                         163                      351   166   0.502      0.386      0.91 (0.73--1.13)      0.507
  rs12356193            141                       55                   5        0.162                         483                      184   18    0.161      0.958      1.01 (0.75--1.36)      0.778
  rs17300741            60                        101                 38        0.445                         181                      344   156   0.482      0.194      0.86 (0.69--1.08)      0.270
  rs505802              102                       84                  16        0.287                         335                      298   56    0.298      0.687      0.95 (0.74--1.21)      0.923

Numbers of genotypes (11, 12, 22) according to alleles from [Table 3](#pone-0007729-t003){ref-type="table"}.

Model including medication with diuretics, lipid lowering and antihypertensive therapy, HDL-C, type 2 diabetes, smoking, and BMI.

### Association analysis of SNPs in the CAD/MI case-control sample {#s3b2}

Deviation from HWE was not observed for the genotyped markers in CAD/MI cases and CAD/MI-free controls (*p*\>0.05). No association with CAD was found for any of the analyzed SNPs ([Table 7](#pone-0007729-t007){ref-type="table"}). Again, adjustment for differentially distributed risk factors between CAD cases and controls did not alter the results significantly ([Table 7](#pone-0007729-t007){ref-type="table"}). The power to detect nominal association with CAD was \>30.3% for an assumed OR = 1.2 and \>79.6% for an OR = 1.4 ([Table 7](#pone-0007729-t007){ref-type="table"}).

10.1371/journal.pone.0007729.t007

###### Association analysis results in CAD case-control sample.
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                CAD case genotypes   CAD-free control genotypes   Allelic   Allelic OR   Adjusted [a](#nt122){ref-type="table-fn"}   Power [b](#nt123){ref-type="table-fn"}   Power [b](#nt123){ref-type="table-fn"}                                                      
  ------------ -------------------- ---------------------------- --------- ------------ ------------------------------------------- ---------------------------------------- ---------------------------------------- ------- ------- ------------------- ------- ------- -------
  rs12129861           379                      712                 355       0.492                         329                                       605                                      288                     0.483   0.537   1.04 (0.93--1.15)   0.785   0.655   0.992
  rs780094             539                      691                 228       0.393                         433                                       603                                      198                     0.405   0.393   0.95 (0.85--1.06)   0.125   0.639   0.991
  rs734553             817                      505                 89        0.242                         726                                       404                                       59                     0.220   0.055   1.14 (1.00--1.29)   0.984   0.509   0.964
  rs2231142           1,140                     305                 16        0.115                         991                                       226                                       13                     0.102   0.131   1.14 (0.96--1.36)   0.055   0.303   0.796
  rs742132             715                      607                 137       0.302                         606                                       495                                      129                     0.306   0.740   0.98 (0.87--1.10)   0.543   0.593   0.985
  rs1183201            385                      743                 321       0.478                         320                                       608                                      290                     0.488   0.477   0.96 (0.86--1.07)   0.638   0.655   0.992
  rs12356193          1,026                     389                 36        0.159                         848                                       353                                       29                     0.167   0.417   0.94 (0.81--1.09)   0.065   0.432   0.926
  rs17300741           385                      686                 368       0.494                         336                                       315                                      273                     0.474   0.149   1.08 (0.97--1.21)   0.745   0.655   0.992
  rs505802             681                      641                 136       0.313                         595                                       520                                      115                     0.305   0.516   1.04 (0.93--1.17)   0.996   0.592   0.984

Numbers of genotypes (11, 12, 22) according to alleles from [Table 3](#pone-0007729-t003){ref-type="table"}.

Model including age at inclusion, gender, hypercholesterolemia, diabetes, hypertension, smoking, and BMI.

Power was calculated for the given OR using the respective MAF in controls and a two-tailed *p* = 0.05.

Discussion {#s4}
==========

In the present case-control association studies, we evaluated the relationship of common SNPs with gout and their potential influence on CAD. The variants are located in nine different genetic regions, four of which are known and the remaining five loci were only recently identified to be associated with serum UA levels in a large meta-analysis of GWA studies [@pone.0007729-Kolz1]. We were able to confirm significant association between gout and SNPs in two established genes, namely *SLC2A9* (rs734553 and rs6855911) and *ABCG2* (rs2231142). However, for markers in the other known and novel loci, no association with the clinical phenotype gout was found in our study. Moreover, our results indicate no relevant influence of the investigated polymorphisms on CAD susceptibility in our German MI Family Study.

The strongest association signal with gout was detected for intronic SNPs rs6855911 and rs734553 in the *SLC2A9* gene, which is consistent with previous studies on gout and serum UA levels [@pone.0007729-Li1]--[@pone.0007729-Dehghan1]. *SLC2A9* is coding for GLUT9, a high-capacity urate transporter, which is abundantly expressed in liver and kidney tissues [@pone.0007729-Anzai1]--[@pone.0007729-Matsuo1]. It is noteworthy that both SNPs located in *SLC2A9* gene showed deviation from HWE in gout cases, which can in some degree support a true association [@pone.0007729-Lee1], [@pone.0007729-Xu1].

In addition, we found a significant association between the exonic SNP rs2231142 in *ABCG2* and gout, again supporting the results of a prior GWA on serum UA levels and gout [@pone.0007729-Dehghan1]. This is the only marker examined that leads to a missense mutation with an amino acid exchange from glutamine to lysine at position 141 in ABCG2 transporter and therefore could have a direct and causal influence on development of the disease [@pone.0007729-Dehghan1]. It is notable, however, that the effect of this variant on susceptibility to gout is only present in our male subcohort.

A recent meta-analysis documented an additional locus on chromosome 6p23-p21.3 encompassing three members of the solute carrier family 17 (SLC17A1, SLC17A3 and SLC17A4) to be associated with serum UA levels [@pone.0007729-Kolz1]. Interestingly, their top marker rs1183201 in the *SLC17A1* gene did not show significant association with the qualitative trait of gout in our study. Another SNP marker, rs1165205 in *SLC17A3*, which is in strong LD with rs1183201 in *SLC17A1* was previously found to be related to serum UA levels and also representing a risk factor for gout [@pone.0007729-Dehghan1]. A possible explanation for these discrepancies may lie in the different recruitment strategies of the study populations and the distinct definition of the phenotype "gout". While Kolz et al. [@pone.0007729-Kolz1] in their meta-analysis examined participants of European ancestry from 14 different study cohorts with widely varying initial inclusion criteria -- potentially concealing a substructure which could lead to false positive results -- our ascertainment approach was to recruit individuals with a strong familial history of CAD from all over Germany with a concomitant accumulation of cardiometabolic risk factors, such as gout. On the other hand, Deghan et al. [@pone.0007729-Dehghan1] included participants from three large population-based studies (Framingham cohort, Rotterdam cohort and the Atherosclerosis Risk in Communities (ARIC) study) with different definitions of gout in each of the study cohorts. It is important to notice, that the allele frequencies between Deghan et al. (rs1165205) [@pone.0007729-Dehghan1], Kolz et al. [@pone.0007729-Kolz1] and our present study (both rs1183201) did not differ substantially (47%, 48% and 48%, respectively).

The same might hold true for the other SNPs that were genotyped in our present study but showed no significant association with the phenotype gout. However, one has to emphasize that in our study, we explicitly investigated the role of SNP markers with clinically manifest gout or gouty arthritis, for which elevated serum UA levels are an important but not a mandatory risk factor [@pone.0007729-Annemans1], [@pone.0007729-Mandell1]. Therefore, differences in the pathophysiological pathways of the development of elevated serum UA levels and the ignition of the inflammatory process of gout or gouty arthritis may account for the distinct findings of our study. This is also reflected by the clinical observations that many patients with high serum UA levels never experience an attack of gout, whereas other people in the absence of hyperuricemia suffer from severe and recurrent flares of gouty arthritis [@pone.0007729-Mandell1]. One can speculate that other pathophysiological mechanisms might be involved, or a complex interplay of genes and their variants lead to the manifestation of the disease. For example, the well-known URAT1 transporter, encoded by *SLC22A12* gene, is involved in renal urate exchange [@pone.0007729-Enomoto1], and a *SLC22A12* polymorphism is also linked to serum UA levels [@pone.0007729-Kolz1]. Therefore, this gene is a strong candidate for gout, but does not show significant association with the clinical phenotype in this and a previous study [@pone.0007729-Dehghan1]. Another possible explanation is the small effect size of some polymorphisms on serum UA levels that could directly impact susceptibility to gout. Our present study showed a high degree of association between gout and SNPs in *ABCG2* and *SLC2A9*, those polymorphisms that were reported to have highest effects on serum UA levels found in the previous meta-analysis (explaining 0.57% and 3.53% of variability, respectively) [@pone.0007729-Kolz1] and that showed ORs for gout between 1.37 and 1.52 in our study. All other SNPs were significant on a genome-wide level, but explained less the variability of serum UA levels (below 0.2%) [@pone.0007729-Kolz1]. Therefore, either power was not sufficient for detection of association between these SNPs and gout in the present study, or their relevance on the clinical phenotype gout is not evident.

Additionally, we found only weak epistatic interaction between SNPs in *SLC2A9* and *LRRC16A* on gout, making a relevant additive effect of SNPs influencing serum UA levels on the qualitative trait unlikely. Potential confounders, such as different medications and prevalence of type 2 diabetes, smoking or BMI, did not influence the association results significantly. Taken together, it is obvious that SNPs with highest influence on serum UA levels could be directly linked to susceptibility to gout, whereas the relevance of less contributing polymorphisms is still arguable.

More complex functional studies are warranted in the future to elucidate the pathways with which the newly identified genes impact serum UA levels and development of gout.

Furthermore, the presence of hyperuricemia and gout has often been discussed to be a cardiovascular risk factor [@pone.0007729-Abbott1]--[@pone.0007729-Feig1]. We thus examined the SNPs being associated with elevated UA serum levels in our second case-control study consisting of CAD cases and controls from the general population. Here, we did not detect a direct genetic relationship between the tested SNPs and CAD. One possible explanation may be limited power: polymorphisms with a small effect on disease susceptibility require very large study samples to be detected. Therefore, we cannot rule out a causal link between the SNPs influencing serum UA levels and CAD. On the other hand, CAD is possibly a more heterogeneous disorder than gout, even on genetic level. For example, no genes known to influence serum UA levels were identified by recent GWA studies on CAD, but genetic loci involved in several different pathways were found [@pone.0007729-Erdmann1], [@pone.0007729-Samani1], [@pone.0007729-Wellcome1]--[@pone.0007729-Tregouet1].

There are limitations in our study design that have to be considered. First, we do not have measurement of serum UA levels in our cohort. Hence, we can not directly replicate the findings of Kolz et al. on serum UA levels [@pone.0007729-Kolz1]. However, we did not aim in replication of serum UA level association but in expansion of these results to clinical manifestation of the phenotypes gout and CAD. Second, all phenotypes were assessed retrospectively from patient documentations and medical history readings. When gout was diagnosed by a physician according to ICD-9 code 274, the phenotype gout was considered as confirmed. In case of self-reported gout, additional intake of uricostatic or uricosuric medication was required to affirm the diagnosis of gout. We have follow-up data from more than 80% of our study participants and, therefore, validation of clinicial phenotypes is available. Third, the power to analyze gender effects in our study is limited. As previously described, association of serum UA levels depends to some degree on gender [@pone.0007729-Dring1]. Our findings on gender-specific association between male but not female gout patients and rs2231142 in *ABCG2* gene are likely to be true positive results but some other gender effects may have been overlooked. Forth, assuming that gout is a risk factor for CAD, we expected to observe significantly more CAD patients in the gout sample than in gout-free controls. However, based on our initial ascertainment strategy where we retrospectively identified gout patients and gout-free controls from a MI/CAD study cohort, we did not find a significant coincidence of CAD and gout. On the other hand, in our CAD case-control sample we found that the clinical phenotype of gout seems to be associated with CAD.

In conclusion, we performed a comprehensive analysis on association with susceptibility to gout and CAD of recently published polymorphisms known to be linked with serum UA levels. Markers in *SLC2A9* and *ABCG2* genes are strongly associated with clinical manifestation of gout in the German MI Family Study. With the knowledge of a comprehensive number of genetic polymorphisms contributing to gout, genetic testing as a supportive diagnostic tool would be conceivable.
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